In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3620-3627

  Caspers, Patrick ^a   Bury, Luc ^a   Gaucher, Bérangère ^a   Heim, Jutta ^a   Shapiro, Stuart ^a   Siegrist, Sibylle ^a   Schmitt Hoffmann, Anne ^a   Thenoz, Laure ^a   Urwyler, Heinrich ^a  

^a BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BAL 0030543; BAL 0030544; BAL 0030545; DIHYDROFOLATE REDUCTASE; PHTHALAZINE DERIVATIVE; THYMIDINE; TRIMETHOPRIM; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENOTOXICITY; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEPTICEMIA; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; ENTEROCOCCUS; FOLIC ACID ANTAGONISTS; HAEMOPHILUS INFLUENZAE; HELA CELLS; HUMANS; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MORAXELLA (BRANHAMELLA) CATARRHALIS; MYCOBACTERIUM AVIUM; PHTHALAZINES; POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

EID: 70349147842     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00377-09     Document Type: Article

References (50)

1. Barrow, E. W., W. J. Suling, L. E. Seitz, R. C. Reynolds, and W. W. Barrow. 2006. New antifolate inhibitors for Mycobacterium avium. Med. Chem. 2:505-510.
2. Bhalla, A., D. C. Aron, and C. J. Donskey. 2007. Staphylococcus aureus intestinal colonization is associated with increased frequency of S. aureus on skin of hospitalized patients. BMC Infect. Dis. 7:105.
3. Biedenbach, D. J., J. M. Bell, H. S. Sader, J. D. Turnidge, and R. N. Jones. 2009. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob. Agents Chemother. 53:1260-1263.
4. Blasi, F., D. J. Farrell, and L. Dubreuil. 2009. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin Study year 5 (2003-2004). Diagn. Microbiol. Infect. Dis. 63:302-308.
5. Bogdanovich, T., L. M. Ednie, S. Shapiro, and P. C. Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219.
6. Clark, C., L. M. Ednie, G. Lin, K. Smith, K. Kosowska-Shick, P. McGhee, B. Dewasse, L. Beachel, P. Caspers, B. Gaucher, G. Mert, S. Shapiro, and P. C. Appelbaum. 2009. Antistaphylococcal activity of dihydrophthalazine antifolates, a family of novel antibacterial drugs. Antimicrob. Agents Chemother. 53:1353-1361.
7. Clinical and Laboratory Standards Institute. 2006. M7-A7. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement (M100-S18). Clinical and Laboratory Standards Institute, Wayne, PA.
9. Cobben, D. C. P., P. H. Elsinga, A. van Waarde, and P. L. Jager. 2003. Letter to the editor. Cancer Res. 63:8558-8559.
10. Coll, P. F., V. R. Ausina, J. V. Vernis, B. O. Mirelis, and G. P. Prats. 1984. Exogenous thymidine and reversal of the inhibitory effect of sulfamethoxazole-trimethoprim on streptococci. Eur. J. Clin. Microbiol. 3:424-426.
11. Coque, T. M., K. V. Singh, G. M. Weinstock, and B. E. Murray. 1999. Characterization of dihydrofolate reductase genes from trimethoprim-susceptible and trimethoprim-resistant strains of Enterococcus faecalis. Antimicrob. Agents Chemother. 43:141-147.
12. Critchley, I. A., S. D. Brown, M. M. Traczewski, G. S. Tillotson, and N. Janjic. 2007. National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. faropenem surveillance study. Antimicrob. Agents Chemother. 51:4382-4389.
13. Dale, G. E., C. Broger, P. G. Hartman, H. Langen, M. G. P. Page, R. L. Then, and D. Stüber. 1995. Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermidis ATCC 14990: the origin of the trimethoprim-resistant S1 DHFR from Staphylococcus aureus? J. Bacteriol. 177:2965-2970.
14. Dale, G. E., H. Langen, M. G. P. Page, R. L. Then, and D. Stüber. 1995. Cloning and characterization of a novel, plasmid-encoded trimethoprim-resistant dihydrofolate reductase from Staphylococcus haemolyticus MUR313. Antimicrob. Agents Chemother. 39:1920-1924.
15. Dale, G. E., C. Broger, A. D'Arcy, P. G. Hartman, R. DeHoogt, S. Jolidon, I. Kompis, A. M. Labhardt, H. Langen, H. Locher, M. G. P. Page, D. Stüber, R. L. Then, B. Wipf, and C. Oefner. 1997. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. J. Mol. Biol. 266:23-30.
16. Davies, B. I. 1990. The importance of the geometric mean MIC. J. Antimicrob. Chemother. 25:471-472.
17. Ferone, R., S. R. Bushby, J. J. Burchall, W. D. Moore, and D. Smith. 1975. Identification of Harper-Cawston factor as thymidine phosphorylase and removal from media of substances interfering with susceptibility testing to sulfonamides and diaminopyrimidines. Antimicrob. Agents Chemother. 7:91-98.
18. Flückiger-Isler, S., M. Baumeister, K. Braun, V. Gervais, N. Hasler-Nguyen, R. Reimann, J. Van Gompel, H.-G. Wunderlich, and G. Engelhardt. 2004. Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compounds. Mutat. Res. 558:181-197.
19. Fu, K. P., E. F. Kimble, R. J. Coldreck, and E. A. Konopka. 1984. Antimicrobial susceptibility, growth kinetic and pathogenicity of thymidine-requiring Streptococcus species. Chemotherapy 30:373-378.
20. Fuchs, P. C., A. L. Barry, S. D. Brown, and the Antimicrobial Susceptibility Testing QC Group. 1997. Interpretative criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. J. Clin. Microbiol. 35:125-131.
21. Gangjee, A., Y. Zeng, T. Talreja, J. J. McGuire, R. L. Kisliuk, and S. F. Queener. 2007. Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates. J. Med. Chem. 50:3046-3053.
22. Golan, L., A. Livneh-Kol, E. Gonen, S. Yagel, I. Rosenshine, and N. Y. Shpigel. 2009. Mycobacterium avium paratuberculosis invades human small-intestinal goblet cells and elicits inflammation. J. Infect. Dis. 199:350-354.
23. Gonzalez, A. H., O. G. Berlin, and D. A. Bruckner. 1989. In-vitro activity of dapsone and two potentiators against Mycobacterium avium complex. J. Antimicrob. Chemother. 24:19-22.
24. Grim, S. A., R. P. Rapp, C. A. Martin, and M. E. Evans. 2005. Trimethoprimsulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 25:253-264.
25. Guerry, P., C. Hubschwerlen, S. Jolidon, J.-L. Specklin, and P. Wyss. September 2000. Substituted 2,4-diaminopyrimidines. U.S. patent 6,114,330.
26. Hamilton-Miller, J. M. T. 1988. Reversal of activity of trimethoprim against gram-positive cocci by thymidine, thymine and 'folates.' J. Antimicrob. Chemother. 22:35-39.
27. Heller, S., L. Kellenberger, and S. Shapiro. 2007. Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic. Antimicrob. Agents Chemother. 51:1956-1961.
28. Johnson, M. I., D. Merrilees, W. A. Robson, T. Lennon, J. Masters, K. E. Orr, J. N. S. Matthews, and D. E. Neal. 2007. Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. Br. J. Urol. Int. 100:826-829.
29. Juste, R. A., N. Elguezabal, A. Pavón, J. M. Garrido, M. Geijo, I. Sevilla, J. L. Cabriada, A. Tejada, F. García-Campos, R. Casado, I. Ochotorena, and A. Izeta. 2009. Association between Mycobacterium avium subsp. paratuberculosis DNA in blood and cellular and humoral immune response in inflammatory bowel disease patients and controls. Int. J. Infect. Dis. 13:247-254.
30. Kasperbauer, S. H., and C. L. Daley. 2008. Diagnosis and treatment of infections due to Mycobacterium avium complex. Semin. Respir. Crit. Care Med. 29:569-576.
31. Koch, A. E., and J. J. Burchall. 1971. Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media. Appl. Microbiol. 22:812-817.
32. Miller, L. G., F. Perdreau-Remington, G. Rieg, S. Mehdi, J. Perlroth, A. S. Bayer, A. W. Tang, T. O. Phung, and B. Spellberg. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-1453.
33. Minassian, M. A., D. A. Lewis, D. Chattopadhyay, B. Bovill, G. J. Duckworth, and J. D. Williams. 1998. A comparison between single-dose fosfomycin trometamol (Monuril®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women. Int. J. Antimicrob. Agents 10:39-47.
34. Nungester, W. J., A. A. Wolf, and L. F. Jourdonais. 1932. Effect of gastric mucin on virulence of bacteria in intraperitoneal infections in the mouse. Proc. Soc. Exp. Biol. Med. 30:121-122.
35. Pankuch, G. A., D. B. Hoellman, G. Lin, S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 1998. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob. Agents Chemother. 42:3032-3034.
36. Peternel, L., M. Kotnik, A. Preželj, and U. Urleb. 2009. Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits. J. Biomol. Screen. 14:142-150.
37. Qi, W., M. Ender, F. O'Brien, A. Imhof, C. Ruef, N. McCallum, and B. Berger-Bächi. 2005. Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Zürich, Switzerland (2003): prevalence of type IV SCCmec and a new SCCmec element associated with isolates from intravenous drug users. J. Clin. Microbiol. 43:5164-5170.
38. Ramirez, J., C. Mason, J. Ali, and F. A. Lopez. 2008. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients. J. La. State Med. Soc. 160:248-254.
39. Reynolds, R., J. Shackcloth, D. Felmingham, A. MacGowan, et al. 2003. Comparison of BSAC agar dilution and NCCLS broth microdilution MIC methods for in vitro susceptibility testing of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: the BSAC Respiratory Resistance Surveillance Programme. J. Antimicrob. Chemother. 52:925-930.
40. Sekiguchi, J., P. Tharavichitkul, T. Miyoshi-Akiyama, V. Chupia, T. Fujino, M. Araake, A. Irie, K. Morita, T. Kuratsuji, and T. Kirikae. 2005. Cloning and characterization of a novel trimethoprim-resistant dihydrofolate reductase from a nosocomial isolate of Staphylococcus aureus CM.S2. Antimicrob. Agents Chemother. 49:3948-3951.
41. Shivde, S. R., R. P. D. Cooke, W. A. O'Neill, A. G. A. Cowie, W. T. Lawrence, and G. M. Watson. 2002. Trimethoprim versus gentamicin for the prevention of bacteriuria following transrectal biopsy of the prostate - do patients need additional anaerobic cover? Urol. Int. 69:106-110.
42. Soto, C. Y., N. Andreu, I. Gibert, and M. Luquin. 2002. Simple and rapid differentiation of Mycobacterium tuberculosis H37Ra from M. tuberculosis clinical isolates through two cytochemical tests using neutral red and Nile blue stains. J. Clin. Microbiol. 40:3021-3024.
43. Stamm, W. E., G. W. Counts, K. F. Wagner, D. Martin, D. Gregory, M. McKevitt, M. Turck, and K. K. Holmes. 1980. Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. Ann. Intern. Med. 92:770-775.
44. Suling, W. J., R. C. Reynolds, E. W. Barrow, L. N. Wilson, J. R. Piper, and W. W. Barrow. 1998. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. J. Antimicrob. Chemother. 42:811-815.
45. Then, R. 1993. Discussion: microbiology. J. Chemother. 5:444-446.
46. Thiermann, S., J. Munzinger, and T. Bodmer. 2002. Comparison of phenotypic and genotypic methods for the detection of clarithromycin resistance in Mycobacterium avium. J. Antimicrob. Chemother. 49:679-681. (Pubitemid 34428985)
47. Tokunaga, T., K. Oka, A. Takemoto, Y. Ohtsubo, N. Gotoh, and T. Nishino. 1997. Efficacy of trimethoprim in murine experimental infection with a thymidine kinase-deficient mutant of Escherichia coli. Antimicrob. Agents Chemother. 41:1042-1045. (Pubitemid 27194182)
48. 18F-FDG for differentiating tumor from inflammation in a rodent model. J. Nucl. Med. 45:695-700.
49. von der Hude, W., S. Kalweit, G. Engelhardt, S. McKiernan, P. Kasper, R. Slacik-Erben, H. G. Miltenburger, N. Honarvar, R. Fahrig, B. Görlitz, S. Albertini, S. Kirchner, D. Utesch, F. Pötter-Locher, H. Stopper, and S. Madle. 2000. In vitro micronucleus assay with Chinese hamster V79 cells - results of a collaborative study with in situ exposure to 26 chemical substances. Mutat. Res. 468:137-163.
50. Wyss, P. C., P. Guerry, P. G. Hartman, C. Hubschwerlen, S. Jolidon, H. Locher, J.-L. Specklin, and H. Stalder. 1999. Anti-MRSA dihydrofolate reductase inhibitors: synthesis and SAR, abstr. 1800. Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.